Enodia Therapeutics

A new approach for targeted protein degradation

Paris, France · Founded 2025 · $25.0M raised

Headquarters
Paris
Founded
2025
Business Model
B2B
Total Funding
$25.0M
Last Round
$25.0M SeedJan 2026
Rounds
1

About

Enodia Therapeutics is a French biotechnology company developing best-in-class small-molecule therapies that target the Sec61 translocon — a novel mechanism enabling degradation of disease-related proteins at the point of synthesis, before they exert pathological effects. Founded in 2025 and originating from foundational research at the Institut Pasteur under Prof. Caroline Demangel, the company was created and incubated by Argobio Studio. Enodia's initial therapeutic focus is inflammatory and autoimmune diseases, targeting previously undruggable secreted and membrane proteins. The company raised €20.7M in early 2026 to advance its targeted protein degradation platform.

Summary

Enodia Therapeutics is a Biotech company based in Paris, France, founded in 2025. It has raised $25.0M in total across 1 round, most recently a $25.0M Seed round in Jan 2026. Investors include Elaia, Pfizer Ventures and Bpifrance.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SeedSeed RoundJan 2026
$25.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Enodia Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/enodia-therapeutics"><img src="https://indexed.vc/api/badge/company/enodia-therapeutics" alt="Enodia Therapeutics on Indexed.vc" width="260" height="76" /></a>